Common Meds Linked to Reduced Immunotherapy Benefit in Lung Cancer Trial

(MedPage Today) — Exposure to proton pump inhibitors (PPIs) was associated with worse progression-free survival (PFS) and overall survival (OS) in patients with locally advanced non-small cell lung cancer (NSCLC) who were treated with durvalumab…